

The impact on vaccination coverage following introduction of a routine pneumococcal vaccination programme for the elderly in Japan



Aiko Shono^{a,*}, Shu-ling Hoshi^b, Masahide Kondo^b

^aDepartment of Public Health and Epidemiology, Faculty of Pharmaceutical Sciences, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan

^bDepartment of Health Care Policy and Health Economics, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8577, Japan

ARTICLE INFO

Article history:

Received 26 December 2017
Received in revised form 7 June 2018
Accepted 9 August 2018
Available online 22 August 2018

Keywords:

Elderly
Pneumococcal
Vaccination
Routine programme

ABSTRACT

In October 2014, a routine pneumococcal vaccination programme in the elderly aged 65–100 years old was initiated in Japan. Currently, this programme is within a transitional period. Eligibility for subsidy under the programme is granted for target ages in 5-year increments, over a 5-year roll-out period. We assessed the impact of the routine vaccination programme on vaccination coverage and explored the factors relating to pneumococcal vaccine uptake. We conducted a cross-sectional web-based survey in 2015 for respondents aged 65–79 years. A total of 3889 respondents answered the survey. The vaccination coverage in this study was estimated as 33.5%. Of the total respondents, 3327 were not vaccinated at initiation of the routine vaccination programme. The uptake of vaccination after implementation of the programme among them was 22.3%. There was a significant relationship between vaccination and eligibility for subsidy under the routine vaccination programme (adjusted odds ratio: 16.7). While there are some limitations to this study, introduction of the routine vaccination programme might affect pneumococcal vaccination coverage in the elderly.

© 2018 Published by Elsevier Ltd.

1. Introduction

Pneumococcal infection carries the risk of serious infection, hospitalisation and even death, especially in older people [1,2]. Pneumococcal vaccines are effective in prevention of invasive pneumococcal disease (IPD) in healthy adults [3,4]. Pneumococcal polysaccharide vaccine (PPSV) 23 and/or pneumococcal conjugate vaccine (PCV) 13 are recommended for vaccination of older people in many countries, including the USA [5], UK [6], Germany [6], Canada [7], Singapore [8], and Taiwan [9].

In Japan, pneumonia is the third leading cause of death (96.5 per 100,000 population in 2015), and this type of death is particularly high in the older population (death caused by pneumococcal disease among those aged ≥ 65 years comprised 97% of the total deaths in 2015) [10]. In October 2014, a routine vaccination programme for the older people, targeting individuals aged 65–100 years, aimed to prevent IPD was initiated by an amendment of the Immunisation Act [11]. During the five-year from 2014 to 2019, this programme has been in a transitional period;

eligibility for subsidy under the programme is granted for those newly of ages 65, 70, 75, 80, 85, 90, 95 or 100 in the fiscal year [11]. Individuals falling within these age criteria are eligible for a subsidised single vaccination per person. The routine vaccination programme is nationwide, but its implementation is decentralised to municipalities which set differing payment amounts, with some municipalities adding their own subsidy schemes such as granting subsidy without age criteria from the first year. While both PCV13 and PPSV23 pneumococcal vaccines are available in Japan, only PPSV23 is subsidised for use in the routine vaccination programme [11].

The national vaccination coverage of pneumococcal vaccines in older people (≥ 65 years) was reported as 38.3% in 2014 (vaccination counts under the national programme divided by eligibility for subsidy for the fiscal year) after the programme started [12]. Vaccination coverage under the new programme was low compared with the influenza vaccine in 2014 (50.6%) [12], and was also lower than the USA (63.6%) [13], UK (69.8%) [14], and Australia (56.0%) [15]. The vaccination coverage in Japan is higher than that in other Asian countries that introduced it as a recommendation, including Taiwan (20.7%, ≥ 75 years) [16] and Singapore (6.1%) [17].

Currently in Japan, the routine pneumococcal vaccination programme represents an ongoing nationwide experiment during

Abbreviations: PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine; IPD, invasive pneumococcal disease.

* Corresponding author.

E-mail address: shono@my-pharm.ac.jp (A. Shono).

the five-year transitional period. In this study, therefore, we assessed the effect of this programme on vaccination coverage in older people. We have also explored the factors relating to pneumococcal vaccine uptake.

2. Methods

We conducted a cross-sectional web-based survey in December 2015. The target population involved those who were registered throughout Japan with a private web survey company because there is no official behavioural surveillance system in Japan. Therefore, this was a closed survey that was only open to individuals that were registered and invited by the survey company [18].

Respondents were aged 65–79 years at the time of this research. This target age was chosen for feasibility of collecting data. For the recruitment process, an invitation was provided to the registered target population through personal websites and e-mail, and people could access the research website. Those who answered the question could obtain some incentives from the survey company, such as points that are exchangeable for gift cards once they reach a certain value.

The respondents were within the target population for the routine vaccination programme, both already eligible for subsidy (i.e. aged 65, 70, 75, 80, 85, 90, 95 or 100 at the end of fiscal year 2014/2015) and not yet eligible for subsidy (all other ages from 65 to 100 years).

The questionnaire mainly comprised 15 queries and was categorized into two parts involving a general part and a health-specific part, including vaccination status. The general part of the questionnaire assessed the following: age (birth month, year), gender, marital status, household income, education background as the final level of education completed, employment status, and children living in the same household. The health-specific part assessed smoking status, pneumococcal and seasonal influenza vaccination status, and any disease under treatment. The queries regarding pneumococcal vaccination also included the timing of vaccination (calendar year and month of vaccination) and the reason for seeking this vaccination. The reason for vaccination was queried to obtain information on the influence of the media and other resources. We did not differentiate between PPSV23 and PCV13 in this study because we aimed to focus on the vaccination trend and ease of response.

Firstly, we estimated the vaccination coverage (vaccinated population divided by target population) to investigate the effect of the routine vaccination programme. Second, we analysed the relationship between pneumococcal vaccination after programme implementation and the factors affecting vaccination uptake using a logistic regression model. These factors were as follows: eligibility for subsidy, age, gender, marital status, education, employment status, smoking status, seasonal influenza vaccination status, any disease under treatment, children within the same household, and household income. In addition, the main reason for vaccination was analysed as summary statistics.

Only respondents who provided informed consent were included in this study. This study was approved by the ethical committee at Meiji Pharmaceutical University.

3. Results

The total number of valid responses was 3889 (total respondents). The median amount of time to complete the questionnaire was 2 min and 23 s. Summary statistics are shown in Table 1. The average age of respondents was 70.8 years old at the time of survey, with males accounting for 1830 (47.1%). The proportion of respondents with a marital status was 77.1%, high school graduate

was the most common educational background, and the proportion of employed respondents was 24.4%. The proportion answering “never smoked” was 60.6% and “ever smoked but currently do not smoke” was 29.6%. Influenza vaccination status was as follows: 44.3% for “annual vaccination”, 36.0% for “never vaccinated”. The proportion of respondents with any disease under treatment was 59.2% and that for having children within the same household was 2.7%. Household income data was available for 3090 respondents (79.5%), with a mode and median of 3–4 million yen (27,000–36,000 USD, 1USD = 110JPY) and 4.2 million yen (38,000 USD), respectively.

We estimated the vaccination coverage in this study from the total respondents and from those who were not vaccinated at introduction of the routine vaccination programme. A total of 1304 (33.5% of the total respondents, 1304/3889) respondents answered that they had been vaccinated with the pneumococcal vaccine at the time of the survey (vaccinated respondents) (Table 1). The vaccination coverage of the total respondents by age is shown in Fig. 1.

Of the total respondents, 3327 (85.5%, 3327/3889) were not vaccinated at initiation of the routine vaccination programme. During the second fiscal year after introduction, a total of 1368 respondents aged 65, 66, 70, 71, 75, 76 or 80 comprised the eligible population within our survey (41.1%, 1368/3327). Seven hundred and forty-two respondents (22.3%, 742/3327) were vaccinated after implementation of the programme. While 619 of 742 (83.4%) vaccinated respondents were eligible for subsidy under the programme, 123 (16.6%, 123/742) vaccinated respondents were not.

The effect of programme implementation was explored as a regression model based on the 3327 respondents who were not vaccinated at programme initiation (Table 2). There was a significant relationship between vaccination and eligibility for subsidy under the routine vaccination programme in the unadjusted and adjusted models (odds ratio: 12.3; 95% confidence interval: 10.0–15.2 for unadjusted and 16.7; 12.6–22.0 for adjusted). There were also relationships between vaccination and the following factors: age, employment status, influenza vaccination status, any disease under treatment, and household income in the adjusted model.

The main reason for vaccination after introduction of the routine vaccination programme was notification by post from municipalities (49.7%), followed by recommendation by a family doctor (16.7%), and commercial information from pharmaceutical companies through television (12.9%) (Table 1). Those who were already eligible for the routine vaccination programme answered that notification by post from municipalities was the main reason for vaccination. The main reason for vaccination in those who were not eligible was the family doctor, followed by notification by post.

4. Discussion

Currently in Japan, the routine pneumococcal vaccination programme for older people (≥ 65 years old) is within a transitional period. At the time this survey was performed, the programme was in its second year of a 5-year roll-out and 41.1% of respondents in this study were eligible for subsidised vaccination. Eligibility for subsidy under the routine vaccination programme was found to have an effect on coverage (Fig. 1), and it had the largest odds ratio (adjusted odds ratio: 16.7) among the factors affecting vaccination uptake. Therefore, introduction of the routine vaccination programme has had an effect on pneumococcal vaccination coverage in older people, similar to the effect observed in Australia following introduction of universal funding [15].

In this study, vaccine uptake differed according to the respondents' factors, such as any disease under treatment, household

Table 1
Summary statistics.

Attributes	Total respondents N = 3889		Respondents who were not vaccinated at the point of introduction of the routine vaccination programme N = 3327		
	Count	%	Count	%	
Age					
65–69	1665	42.8	1542	46.3	
70–74	1364	35.1	1139	34.2	
75–79	860	22.1	646	19.4	
Gender (male)	1830	47.1	1566	47.1	
Marital status (yes)	3000	77.1	2560	76.9	
Education background					
Junior high school	212	5.5	188	5.7	
High school	1868	48.0	1601	48.1	
College	593	15.3	509	15.3	
University	1139	29.3	970	29.2	
Graduate school	71	1.8	54	1.6	
Others or no answer	6	0.2	5	0.2	
Employment (yes)	948	24.4	850	25.5	
Smoking					
Yes	382	9.8	345	10.4	
Never	2355	60.6	1991	59.8	
Ever smoked	1152	29.6	991	29.8	
Influenza vaccination					
Never	1401	36.0	1338	40.2	
Annually	1723	44.3	1317	39.6	
Sometimes	765	19.7	672	20.2	
Any disease under the treatment (yes)	2302	59.2	1892	56.9	
Children within the same household (yes)	105	2.7	91	2.7	
Eligible for subsidy ¹	–	–	1368	41.1	
Pneumococcal vaccination (yes)	1304	33.5	742	22.3	
Main reason for vaccination			Respondents who were vaccinated after implementation of the programme N = 742		
			Count	%	
Postal information from municipalities			369	49.7	
Recommendation by a doctor			124	16.7	
Commercial information via television ²			96	12.9	
Recommendation by family member			50	6.7	
Public information from municipalities			35	4.7	
Commercial information at clinic or hospital			21	2.8	
Information from friends			20	2.7	
Commercial information via newspaper			18	2.4	
Others			6	0.8	
None			3	0.4	
Income per yr (million yen) ³	(Thousand USD)	N	%	N	%
<1	<9	101	2.6	85	2.6
1–2	9–18	332	8.5	289	8.7
2–3	18–27	631	16.2	547	16.4
3–4	27–36	753	19.4	636	19.1
4–5	36–45	505	13.0	424	12.7
5–6	45–55	272	7.0	238	7.2
6–7	55–64	137	3.5	115	3.5
7–8	64–73	89	2.3	75	2.3
8–9	73–82	70	1.8	60	1.8
9–10	82–91	69	1.8	60	1.8
10–15	91–136	89	2.3	79	2.4
15≤	136≤	42	1.1	29	0.9
no answer	–	799	20.6	690	20.7

¹ For the routine vaccination programme. Individuals who were already vaccinated at the time of programme introduction were not eligible for subsidy under the routine vaccination programme.

² From pharmaceutical companies through television.

³ Respondents could answer from one million yen (9000 USD) to 15 million yen or more (136,000 USD) and they could also select “do not know/do not want to answer”. 1USD = 110JPY.

income, age, and employment. Respondents undergoing any treatment were likely to be vaccinated, which was also found in other countries [19]. Recipients in Japan are required to pay about 3000 JPY (27 USD) as the median copayment for vaccination under the routine vaccination programme [20]. Therefore, income could be a factor influencing vaccine uptake [21]. This was also shown

for seasonal influenza vaccination for adults and children in Japan [22–24]. However, some studies on vaccination in other countries showed no associations with income [21,25]. Influenza vaccine uptake is also related to that of the pneumococcal vaccine, and risk perception is further considered to be a factor [19,26]. Furthermore, in our study, a higher age of the respondents, especially




Fig. 1. Vaccination coverage by age*. *Age at the end of fiscal year.

Table 2

Logistic regression model for vaccine uptake under the routine pneumococcal vaccination programme.

	Unadjusted odds ratio	95%CI		Adjusted odds ratio	95%CI	
Age	0.99	0.97	1.01	1.04	1.01	1.07
Gender (male; 1)	0.98	0.84	1.16	1.23	0.91	1.66
Marital Status (yes; 1)	1.24	1.01	1.51	1.24	0.80	1.94
Education (year)	1.01	0.98	1.05	1.00	0.95	1.07
Employment (yes; 1)	0.92	0.76	1.11	0.64	0.48	0.86
Smoking status						
Smoking	–					
Never	1.34	1.00	1.80	1.28	0.82	1.98
Ever smoked	1.27	0.93	1.73	1.24	0.79	1.93
Influenza vaccination						
Never	–					
Annually	3.55	2.91	4.34	4.86	3.63	6.50
Sometimes	1.90	1.48	2.43	2.00	1.42	2.82
Any disease under treatment (yes; 1)	1.62	1.36	1.92	1.37	1.07	1.77
Children within the same household (yes; 1)	0.96	0.58	1.58	0.72	0.35	1.49
Eligibility for subsidy* (yes; 1)	12.34	9.99	15.24	16.67	12.65	21.96
Income (million yen)	1.0036	1.0003	1.0069	1.0062	1.0018	1.0107

In the unadjusted model, 3327 cases were included, and 2172 were included in the adjusted model. Missing data were excluded in both models.

* For the routine vaccination programme.

older than 75 years, resulted in a tendency to be vaccinated, even though they were not eligible for the subsidy. Other research conducted before introduction of the routine pneumococcal vaccination programme in Japan has also shown that vaccine coverage for those older than 75 years was relatively higher than that for older people aged younger than 74 years [27]. There could be two possible reasons for these findings. Older people may have protective behaviour [28] and they may have more chances to visit doctors who recommend vaccination [29]. With regard to the factor of employment, people who are employed might miss the opportunity to be vaccinated because they have limited time [30].

The municipalities' strategy of posting information directly to those eligible for subsidy was the main trigger for seeking the vaccine in our study. However, the effort spent in promotion of vaccination differed between municipalities. In 2016, 85% of municipalities informed individuals about the vaccination by posted mail [20]. This approach may affect the vaccination behaviour of older people in a similar manner to that seen for human papillomavirus vaccination in the younger generation in Japan [31]. The encouragement by a family doctor could also be effective for the ineligible group because older people may have a higher chance of visiting the family doctor [29].

There are some limitations to this study. First, currently, only PPSV 23 is covered by the subsidy programme, but we did not differentiate between PPSV23 and PCV13. Because we focussed on the vaccination coverage trend for pneumococcal infection by introduction of the subsidy program, we consider that our main conclusions are legitimate. Second, we should consider selection bias. This study was a web-based survey of the spontaneous registered population of a private web survey service. Therefore, respondents in this survey were not selected by random sampling. While the respondents were collected from overall Japan, there was self-selected bias. The age structure (≥ 65 years old) in the target population in this survey and that in Japan is different. Additionally, internet access in Japan is only available for 71.4% of the population aged 65–69 years and in 53.5% of those aged 70–79 years [32]. Therefore, this study might not be representative of Japan. Third, self-reporting bias could also have occurred because we did not confirm the respondents' certificate of their vaccination. Fourth, we did not specifically investigate the effect of any original municipality-instigated programmes before and after introduction of the routine pneumococcal vaccination programme [33]. Fifth, we only included 15 questions. Therefore, we did not examine other factors, such as social factors of the area residence, living

conditions, private insurance, and knowledge on pneumococcal infection that affects vaccination behaviour [21]. Finally, this survey was conducted in the middle of the fiscal year. Therefore, some respondents might not have been vaccinated yet, but intended to be vaccinated. While there are some limitations to our study, we attempted to determine the current situation throughout Japan.

Currently in Japan, the routine pneumococcal vaccination programme is ongoing under the 5-year transitional period, until fiscal year 2018; eligibility for subsidy under the programme is granted for those newly aged 65, 70, 75, 80, 85, 90, 95 or 100 years in the fiscal year. As this is a new trial of vaccine policy by the Japanese government, the process will be finished in fiscal year 2018. After that, the ongoing program of subsidizing vaccination for those newly aged 65 years is assumed to maintain the vaccine coverage among older populations. The study findings may also imply that decentralised efforts by municipalities aimed at new target populations are also required, for example, through use of mass communication, like regular newsletters and through personal communication intended to achieve higher coverage. This implication would be also valid for decentralised local governments in other countries.

In conclusion, under the routine vaccination programme, eligibility for subsidy appears to have a relation to higher coverage (adjusted odds ratio: 16.7). Therefore, introduction of the routine vaccination programme might affect pneumococcal vaccination coverage in older people.

Conflict of interests

None.

Acknowledgements

This study was supported by JSPS KAKENHI Grant Number (25460817) and a research grant for Research on Emerging and Re-emerging Infectious Diseases, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan.

References

- Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalisation among U.S. adults. *NEJM* 2015;373:415–27.
- Centers for disease control and prevention. Pneumococcal vaccination: what everyone should know. <<https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html>> [accessed 28 November 2017].
- Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database of Systematic Reviews* 2013;1:CD000422.
- Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *NEJM* 2015;372:1114–25.
- Centers for disease control and prevention. Pneumococcal vaccine recommendations. <<https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html>> [accessed 6 December 2017].
- European centre for disease prevention and control. Pneumococcal disease: recommended vaccinations. <<https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1>> [accessed 15 March 2018].
- Government of Canada. Pneumococcal vaccine. <<https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html>> [accessed 8 March 2018].
- Ministry of Health. MOH establishes national adult immunisation schedule: extends use of Medisave for vaccines under the schedule. <https://www.moh.gov.sg/content/moh_web/home/pressRoom/pressRoomItemRelease/2017/moh-establishes-national-adult-immunisation-schedule-extends-us.html> [accessed 6 March 2018].
- Centers for disease control, R.O.C. (Taiwan). Invasive pneumococcal disease. <<http://www.cdc.gov.tw/english/info.aspx?treeid=e79c7a9e1e9b1cdf&nowtreeid=e02c24f0dadcd729&tid=00B8C8D154EEAE73>> [accessed 6 March 2018].
- Health, Labour and Welfare Statistics Association. *J Health Welfare Statistics* 2017/2018. [in Japanese].
- National Institute of Infectious Disease. Koreisha no haien kyukin vaccine no teikisesshu ni tuite. 2014 *IASR*;35:240–1. <<https://www.niid.go.jp/niid/ja/iasr-sp/2300-related-articles/related-articles-416/5030-dj4168.html>> [accessed 4 July 2017]. [in Japanese].
- Ministry of Health, Labour and Welfare. Teiki no yobo sesshu jishishasuu. <<http://www.mhlw.go.jp/topics/bcg/other/5.html>> [accessed 7 July 2017]. [in Japanese].
- Williams WW, Lu P, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations—United States, 2015. *MMWR Surveill Summ* 2017;66:1–28.
- Public Health England. Health protection report: pneumococcal polysaccharide vaccine (PPV) coverage report, England, April 2016 to March 2017. <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448406/hpr2615_ppv.pdf> [accessed 5 December 2017].
- Dyda A, Kariki S, Hayen A, MacIntyre CR, Menzies R, Banks E, et al. Influenza and pneumococcal vaccination in Australian adults: a systematic review of coverage and factors associated with uptake. *BMC Infect Dis* 2016;16:515.
- Chen CH, Wu MS, Wu IC. Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan: a nation-wide community-based study. *Medicine (Baltimore)* 2018;97:e9773.
- Ho HJ, Chan YY, Ibrahim MAB, Wagle AA, Wong CM, Chow A. A formative research-guided educational intervention to improve the knowledge and attitudes of seniors towards influenza and pneumococcal vaccinations. *Vaccine* 2017;35:6367–74.18.
- Eysenbach G. Improving the quality of web surveys: the checklist for reporting results of internet E-surveys (CHERRIES). *J Med Internet Res* 2004;6(3):e34.
- Dower J, Donald M, Begum N, Vlack S, Ozolins I. Patterns and determinants of influenza and pneumococcal immunisation among adults with chronic disease living in Queensland, Australia. *Vaccine* 2011;29:3031–7.
- Murakami Y, Nishiwaki Y, Kanazu S, Oba M, Watanabe A. A nationwide survey of PPSV23 vaccine coverage rates and their related factors among the elderly in Japan, 2016. *Nihon Koshu Eisei Zasshi* 2018;65:20–4 [in Japanese].
- Jain A, van Hoek AJ, Boccia D, Thomas SL. Lower vaccine uptake amongst older individuals living alone: a systematic review and meta-analysis of social determinants of vaccine uptake. *Vaccine* 2017;35:2315–28.
- Kondo M, Hoshi SL, Okubo I. Does subsidy work? Price elasticity of demand for influenza vaccination among the elderly in Japan. *Health Policy* 2009;91:269–76.
- Shono A, Kondo M. Factors that affect voluntary vaccination of children in Japan. *Vaccine* 2015;33:1406–11.
- Wada K, Smith DR. Influenza vaccination uptake among the working age population of Japan: results from a national cross-sectional survey. *PLoS One* 2013;8:e59272.
- Ganczak M, Gil K, Korzeń M, Bażydło M. Coverage and influencing determinants of influenza vaccination in elderly patients in a country with a poor vaccination implementation. *Int J Environ Res Public Health* 2017;14.
- Brewer NT, Chapman GB, Gibbons FX, Gerrard M, McCaul KD, Weinstein ND. Meta-analysis of the relationship between risk perception and health behaviour: the example of vaccination. *Health Psychol* 2007;26:136–45.
- Washio S, Kondo R, Fujisawa N, Matsumoto N, Harada E, Tashiro H, et al. Haienkyukin wakutin sesshu koureisya to hi-sesshu koureisya no tokucho. *Jpn J Clin Exp Med* 2016;93:1109–12 [in Japanese].
- Tsai YY, Lee JJ, Hsieh WH. Determinants of the public intent to receive the seasonal influenza vaccine and protective behaviors: a population-based study in Taiwan. *Vaccine* 2014;32:6667–75.
- Szucs TD, Müller D. Influenza vaccination coverage rates in five European countries—a population-based cross-sectional analysis of two consecutive influenza seasons. *Vaccine* 2005;23:5055–63.
- Iwasa T, Wada K. Reasons for and against receiving influenza vaccination in a working age population in Japan: a national cross-sectional study. *BMC Public Health* 2013;13:647.
- Kobayashi H, Nakajima Y, Akasaki M. Factors influencing coverage of human papillomavirus (HPV) vaccination: questionnaire survey of local government in Nara Prefecture about the HPV vaccination program and communication campaigns to promote the program. *Prog Med* 2012;32:753–9 [in Japanese].
- Ministry of Internal Affairs and Communications. White paper information and communications in Japan. <<http://www.soumu.go.jp/johotsusintokei/whitepaper/ja/h28/html/nc252110.html>> [accessed 13 July 2017].
- Kondo M, Yamamura M, Hoshi SL, Okubo I. Demand for pneumococcal vaccination under subsidy program for the elderly in Japan. *BMC Health Serv Res* 2012;12:313.